TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36342940

Group type: EXPERIMENTAL
Intervention: Transportation reimbursement ($5 USD) and up to three reminder phone calls for those not linking within seven days
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group received a clinic referral only
Number of subjects: 199
Study: 32315340

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle and weight-loss intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 35573609

Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 33109455

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon pump (IABP)
Number of subjects: 690
Study: 34057469

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral skills (relaxation, cognitive restructuring, worry practice)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Attention control condition (health management content [HMC])
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Telecoaching (motivational interviewing)
Number of subjects: 196
Study: 33432993

Group type: EXPERIMENTAL
Intervention: Fresh group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Glycerol group (preserved at -78 °C)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: SDS group (0.1% sodium dodecyl sulfate decellularization)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Glycerol group
Number of subjects: 93

Group type: COMPARATOR
Intervention: SDS group
Number of subjects: 93
Study: 35689478

Group type: EXPERIMENTAL
Intervention: NAVIGATE
Number of subjects: 404

Group type: COMPARATOR
Intervention: Community Care (CC)
Number of subjects: 404
Study: 32861806

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg orally, once daily)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Platinum-pemetrexed (pemetrexed plus carboplatin/cisplatin, intravenously, every 3 weeks, ≤6 cycles)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Osimertinib (after crossover adjustment)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 419

Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 419
Study: 36096203

Group type: EXPERIMENTAL
Intervention: Remibrutinib 10 mg once daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Remibrutinib 35 mg once daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Remibrutinib 100 mg once daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Remibrutinib 10 mg twice daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Remibrutinib 25 mg twice daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Remibrutinib 100 mg twice daily
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 34738000

Group type: EXPERIMENTAL
Intervention: High sn-2 palmitic acid (OPO) formula
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 174
Study: 33044367

Group type: EXPERIMENTAL
Intervention: CUR + FEN (500 mg·d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: FEN (300 mg·d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CUR + FEN, FEN, PLA
Number of subjects: 47
Study: 34715091

Group type: EXPERIMENTAL
Intervention: Novel electrocardiogram algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional electrocardiogram algorithm
Number of subjects: 0
Study: 33823421

Group type: EXPERIMENTAL
Intervention: Multi-specialist telemedicine care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual territory care
Number of subjects: 60
Study: 32293914

Group type: EXPERIMENTAL
Intervention: endobronchial induced pluripotent stem cell‐derived human MSCs (hMSCs) (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: cell‐free carrier vehicle (vehicle control; n=7)
Number of subjects: 14
Study: 33772303

Group type: EXPERIMENTAL
Intervention: Human growth hormone (GH) injections (0.050 mg/kg/day) for 12 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Human growth hormone (GH) injections
Number of subjects: 14
Study: 33930115

Group type: EXPERIMENTAL
Intervention: Automated nerve monitoring
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (blinded monitoring)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 34268601

Group type: EXPERIMENTAL
Intervention: Uterine fibroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endometrial cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 0
Study: 32297923

Group type: EXPERIMENTAL
Intervention: Face-down positioning
Number of subjects: 239

Group type: COMPARATOR
Intervention: Support-the-break positioning
Number of subjects: 239
Study: 35678744

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-Volume High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-Exercising Control
Number of subjects: 28
Study: 34972770

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) in a blended format (face-to-face individual UP + online, app-based UP)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Treatment as usual (individual cognitive behavioural therapy)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) in a blended format
Number of subjects: 310
Study: 35449368

Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine plus standard triple antiemetic therapy (aprepitant, tropisetron, dexamethasone)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5 mg olanzapine plus tropisetron and dexamethasone (omitting aprepitant)
Number of subjects: 120
Study: 34127059

Group type: EXPERIMENTAL
Intervention: Acupuncture at GB34
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture at EX‐LE6
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture at non-acupoint (Control)
Number of subjects: 90
Study: 33355079

Group type: COMPARATOR
Intervention: Standard regimen (Group A): omeprazole, amoxicillin, clarithromycin, and bismuth subcitrate for 2 weeks.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sequential regimen (Group B): omeprazole and amoxicillin for 5 days, followed by omeprazole, tinidazole, and levofloxacin for 5 days.
Number of subjects: 160
Study: 35186874

Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children for Teachers (ICC-T) intervention delivered as a 5-day training workshop
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 468
Study: 32460145

Group type: EXPERIMENTAL
Intervention: Specific cognitive rehabilitation (SCR)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonspecific intervention (NSI)
Number of subjects: 35
Study: 33925694

Group type: EXPERIMENTAL
Intervention: Workshop (WS) version of SUCCEAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online (ONL) version of SUCCEAT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workshop (WS) and Online (ONL) versions of SUCCEAT
Number of subjects: 0
Study: 32435820

Group type: EXPERIMENTAL
Intervention: extracorporeal cardiopulmonary resuscitation (eCPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard care (not explicitly mentioned but implied as control)
Number of subjects: 0
Study: 34935724

Group type: EXPERIMENTAL
Intervention: Inhalation of damask rose 40% and lavender 10% essential oils
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine dressing protocol
Number of subjects: 62
Study: 32744426

Group type: COMPARATOR
Intervention: Multimedia psychosocial intervention (MPI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Psychosocial information package (PIP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study: 36196601

Group type: EXPERIMENTAL
Intervention: Inclisiran sodium (900 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33121289

Group type: EXPERIMENTAL
Intervention: 0.5 mg/d melatonin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.5 mg/d melatonin plus 30 minutes of 10,000 lux bright light therapy (BLT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.5 mg/d placebo
Number of subjects: 51
Study: 32118274

Group type: EXPERIMENTAL
Intervention: Cases (death caused by VL)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Controls (cured)
Number of subjects: 360
Study: 33601849

Group type: EXPERIMENTAL
Intervention: Anti-Toxoplasma antibodies (IgG) testing
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Anti-Toxoplasma antibodies (IgM) testing
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: PCR testing for T. gondii DNA
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Avidity test for IgG antibodies
Number of subjects: 500

Group type: COMPARATOR
Intervention: Seropositivity rate comparison
Number of subjects: 500
Study: 34849690

Group type: EXPERIMENTAL
Intervention: Local gentamicin treatment (collagenous carriers containing gentamicin left between sternal halves during sternal refixation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Local gentamicin treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no local antibiotics used)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 33198568

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice a week for 4 weeks + conventional therapy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 26
Study: 34506343

Group type: EXPERIMENTAL
Intervention: ART provided three‐monthly in community ART groups (3MC)
Number of subjects: 10136

Group type: EXPERIMENTAL
Intervention: ART provided 6‐monthly in either CAGs or on an individual provider‐patient basis (6MC)
Number of subjects: 10136

Group type: EXPERIMENTAL
Intervention: ART provided three‐monthly in community ART groups (3MC) and ART provided 6‐monthly (6MC)
Number of subjects: 10136

Group type: COMPARATOR
Intervention: ART collected 3‐monthly at healthcare facilities (3MF)
Number of subjects: 10136
Study: 36429807

Group type: EXPERIMENTAL
Intervention: Health coaching intervention for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 33772131

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 99
Study: 32658385

Group type: EXPERIMENTAL
Intervention: Hyperinsufflation therapy (15 minutes twice daily using a cough assist device over 12 months)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hyperinsufflation therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 34151671

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) from the first day of the cycle to five days before starting ovarian stimulation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2 mg/12 hours of oral E2 valerate from day 25 of the previous cycle until the day before starting stimulation
Number of subjects: 86

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 86
Study: 34496087

Group type: EXPERIMENTAL
Intervention: Nanomicelle curcumin (CUR) 80 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (NS) 1,000 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CUR (80 mg) and NS (1,000 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 120
Study: 34497110

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (pooled doses)
Number of subjects: 8246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study: 32780926

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg over 10 minutes, 0.5 µg/kg/h during surgery, and 1 µg/kg after cardiopulmonary bypass)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 141
Study: 36344766

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg oral nanocrystal formulation for 10 days
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 701
Study: 34880976

Group type: EXPERIMENTAL
Intervention: WeChat platform health management and continuous refined nursing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing after PCI
Number of subjects: 100
Study: 35986308

Group type: EXPERIMENTAL
Intervention: Behavioral designs encouraging savings behavior through SMS text messages plus standard Mama Program offering
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard Mama Program offering
Number of subjects: 700
Study: 33795622

Group type: EXPERIMENTAL
Intervention: ColoWrap
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 350
Study: 32652024

Group type: EXPERIMENTAL
Intervention: 6 g/d of MCTs (MCT group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 6 g/d of long-chain triglycerides (LCT group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: LD + MCT group (1.2 g L-leucine and 20 μg cholecalciferol enriched with 6 g/d of MCTs)
Number of subjects: 64
Study: 35906491

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon angioplasty
Number of subjects: 230

Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 230
Study: 32520897

Group type: EXPERIMENTAL
Intervention: 1:1:1 transfusion ratio
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: High plasma/PRBC and high platelet/PRBC ratios
Number of subjects: 680

Group type: COMPARATOR
Intervention: Low transfusion ratios of plasma and platelets
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Actual transfusion ratios received
Number of subjects: 680
Study: 35078831

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix graft (ADMG) combined with coronally advanced flap (CAF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) combined with coronally advanced flap (CAF)
Number of subjects: 40
Study: 34031695

Group type: EXPERIMENTAL
Intervention: Convalescent plasma containing neutralizing antibody to SARS-CoV-2
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Wild-type SARS-CoV-2 in seronegative individuals
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: B.1.1.7 variant
Number of subjects: 1274
Study: 35152578

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional ovulation induction protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional ovulation induction protocol (Control group)
Number of subjects: 60
Study: 34251406

Group type: EXPERIMENTAL
Intervention: High screen time (>2 hours per day)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Television/computer in the bedroom (yes)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Low screen time (≤2 hours per day)
Number of subjects: 414

Group type: COMPARATOR
Intervention: No television/computer in the bedroom
Number of subjects: 414
Study: 33262937

Group type: EXPERIMENTAL
Intervention: Questionnaire-based pooling
Number of subjects: 25978

Group type: COMPARATOR
Intervention: Random pooling
Number of subjects: 25978
Study: 37380303

Group type: EXPERIMENTAL
Intervention: AF-CBT (n = 65)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standardized AF education (n = 62)
Number of subjects: 127
Study: 33622960

Group type: EXPERIMENTAL
Intervention: Male donor red blood cells (RBCs)
Number of subjects: 8850

Group type: COMPARATOR
Intervention: Female donor red blood cells (RBCs)
Number of subjects: 8850
Study: 32326727

Group type: EXPERIMENTAL
Intervention: Yoga therapy for 12 weeks
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 166
Study: 35125449

Group type: EXPERIMENTAL
Intervention: RIG 1 (POST group)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: RIG 2 (POST group)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: RIG implementation (POST group)
Number of subjects: 1100
Study: 34408458

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV), 3 sessions a week for 8 weeks, in addition to the selected exercise program (balance exercises and resisted exercises)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Selected exercise program (balance exercises and resisted exercises)
Number of subjects: 38
Study: 34697975

Group type: EXPERIMENTAL
Intervention: Cough severity visual analog scale (VAS)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Cough Severity Diary (CSD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Leicester Cough Questionnaire (LCQ)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Patient Global Impression of Change (PGIC) scale
Number of subjects: 253

Group type: COMPARATOR
Intervention: Objective cough frequency
Number of subjects: 253
Study: 32173648

Group type: EXPERIMENTAL
Intervention: Combined medication of risedronate sodium and raloxifene (SERM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate sodium (Control)
Number of subjects: 0
Study: 35799266

Group type: EXPERIMENTAL
Intervention: Novel house design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard house design)
Number of subjects: 0
Study: 32203109

Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1418
Study: 34871577

Group type: EXPERIMENTAL
Intervention: Therapist‐supported online remote behavioural intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Psychoeducation (control group)
Number of subjects: 201
Study: 36171562

Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Esketamine 0.25 mg/kg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Esketamine 0.3 mg/kg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Fentanyl 1 μg/kg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 178
Study: 33481276

Group type: EXPERIMENTAL
Intervention: Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome (MSQ v2.1 ePRO)
Number of subjects: 2850
Study: 32469106

Group type: EXPERIMENTAL
Intervention: Cultural adaptation of motivational interviewing (CAMI)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Motivational interviewing (MI)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: CAMI with high baseline discrimination
Number of subjects: 296
Study: 35797770

Group type: EXPERIMENTAL
Intervention: Subdural Evacuation Port System (SEPS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Burr Hole Evacuation (BHE)
Number of subjects: 160
Study: 33387508

Group type: EXPERIMENTAL
Intervention: Internal mammary and medial supraclavicular lymph node chain irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33115278

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 1653
Study: 34371511

Group type: COMPARATOR
Intervention: Ozil handpiece
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Active Sentry handpiece
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both handpieces
Number of subjects: 204
Study: 33141979

Group type: EXPERIMENTAL
Intervention: AmplifEYE-assisted colonoscopy (AC)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 334
Study: 35147899

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Multidisciplinary Intervention (MDI)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Both interventions (BI and MDI)
Number of subjects: 476
Study: 33596318

Group type: EXPERIMENTAL
Intervention: Genetically determined 25(OH)D increase (per 1-SD increase)
Number of subjects: 4662

Group type: EXPERIMENTAL
Intervention: Observational analysis of plasma 25(OH)D levels
Number of subjects: 4662

Group type: EXPERIMENTAL
Intervention: Genetic risk score for 25(OH)D
Number of subjects: 4662

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 4662
Study: 35112954

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 33851360

Group type: EXPERIMENTAL
Intervention: Bilateral subcapsular orchiectomy (BSO)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bilateral extracapsular orchiectomy (BEO)
Number of subjects: 70
Study: 33136126

Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35838437

Group type: COMPARATOR
Intervention: Repeated assessment (completed surveys at baseline, 3‐, 6‐, and 12‐month follow‐ups)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Minimal assessment (completed surveys at baseline and 12‐month follow‐up)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Repeated assessment
Number of subjects: 456

Group type: COMPARATOR
Intervention: Minimal assessment
Number of subjects: 456
Study: 34086751

Group type: EXPERIMENTAL
Intervention: TAU+ABM (Attentional Bias Modification)
Number of subjects: 169

Group type: COMPARATOR
Intervention: TAU+placebo
Number of subjects: 169

Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 169
Study: 35510322

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both CIT and PLC
Number of subjects: 12
Study: 34960669

Group type: EXPERIMENTAL
Intervention: Selgantolimod (SLGN)
Number of subjects: 0
Study: 35089082

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study: 34271464

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saponin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-application of Bacillus subtilis and saponin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis and saponin
Number of subjects: 0